Former Chief Financial Officer · Damora Therapeutics, Inc. (DMRA)

Jonathan Freve

A named executive officer of Damora Therapeutics in every fiscal year CompBrief holds from FY2021 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$819,754

Salary $328,182Stock awards $71,000

FY2023: $701,329

3rd of 4 named executive officers at Damora Therapeutics by FY2024 total.

4 named officers on file for Damora Therapeutics, FY2024

Jonathan Freve’s pay file — $29

  • 4 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Damora Therapeutics’s whole pay program stands against its peers

  • Damora Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on DMRA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 30, 2025 (DEF 14A).

Free

Get Jonathan Freve’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Jonathan Freve compensation by year

Damora Therapeutics Summary Compensation Table · all 4 fiscal years held
In US dollars, as Damora Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021FY2022FY2023FY2024
Salary$420,000$441,506$458,640$328,182
Bonus$161,000$141,120$110,100$0
Stock awards$0$0$0$71,000
Option awards$912,491$284,187$106,789$0
Non-equity incentive$0$0$0$0
Pension and deferred compensation$0$0$0$0
All other$21,400$22,300$25,800$420,572
Total$1,514,891$889,113$701,329$819,754

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Damora Therapeutics, Inc. DEF 14A filed April 30, 2025, accession 0000950170-25-060552, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Damora Therapeutics, Inc. filed document, accession 0000950170-25-060552. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2025.

$1.5M
$889K
$701K
$820K
FY21
FY22
FY23
FY24
SalaryBonusStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
Option18,090—$1.95
Option25,730—$13.00
Option61,849—$3.24
Option115,000—$1.21

Per the Outstanding Equity Awards at Fiscal Year-End table in Damora Therapeutics, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Damora Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Hans SchambyeFormer President and Chief Executive Officer$1,429,550
Garrett WinslowGeneral Counsel$897,368
Jonathan Freve · this pageFormer Chief Financial Officer$819,754
Lori FirmaniChief Financial Officer$561,892

The full Damora Therapeutics compensation record

free company brief

This page is one person within Damora Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Damora Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Jonathan Freve's compensation dossier · One-time report. No refunds.